In the latest episode of Health Law Diagnosed, host Bridgette Keller dives into potential health care policy changes on the horizon following ...

With morale at a low point, biotech and pharma CEOs are cautiously optimistic about the incoming Trump administration.

Here’s the bad news: The $6 billion the government is supposed to save from drug price negotiations is very close to the amount Medicare has already lost thanks to Big Pharma’s abuse of the ...

Trump’s pick to lead the Health Department is targeting a multibillion-dollar ad market that’s one of the biggest spenders on ...

Big Pharma is hiding a massive secret about so-called miracle weight-loss drugs like Ozempic – they come with a raft of potentially devastating side effects and can also trap users on an endless ...

As the year draws to a close, Wall Street is set to crown Eli Lilly (NYSE:LLY) among the best in Big Pharma, while Novo Nordisk (NVO), its closest rival in the lucrative obesity drug market ...

My weight concerns mainly injure my considerable vanity, and I’m not about to outsource my self-esteem issue to Big Pharma if I don’t have to. I once remarked semi-seriously that my epitaph ...

The article discusses six major constituents of the Invesco Pharmaceuticals ETF PJP: Pfizer, Amgen, Gilead Sciences, AbbVie, Bristol-Myers Squibb, and Merck & Co. The focus lies on the ...

Analysts casting their eyes forward to 2022 see big pharma maintaining its position in the sector, protected by vast war chests and ready to pounce on any newcomer that shows promise. In the ...

As investors turned apprehensive in the later half of 2024, all eyes turned to Pharma. Nifty Pharma gained 29 per cent in the last year, which is the highest among the large sectors, as it is ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on. In separate presentations, the CEOs of Bristol Myers Squibb, Pfizer and Merck ...